Statistical Analysis
Statistical testing to measure the association of these drugs with the
specified cardiac events of interest was performed using
disproportionality signal analysis. These were presented as reporting
odds ratios (RORs) of reported cardiac adverse events concomitant with
the use of a newly approved multiple myeloma agent compared to the same
reported adverse events within the entire database of pharmaceuticals
within FAERS. The ROR was considered significant when the lower limit of
the 95% CI was >1.0.